Based on the Drägerwerk AG & Co. KGaA stock forecast from 0 analysts, the average analyst target price for Drägerwerk AG & Co. KGaA is not available over the next 12 months. Drägerwerk AG & Co. KGaA’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Drägerwerk AG & Co. KGaA is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Drägerwerk AG & Co. KGaA’s stock price was USD 51.00. Drägerwerk AG & Co. KGaA’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +28.89% over the last year.
No recent analyst target price found for Drägerwerk AG & Co. KGaA
No recent average analyst rating found for Drägerwerk AG & Co. KGaA
Company Overview Drägerwerk AG & Co. KGaA
Drägerwerk AG & Co. KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection. Its products portfolio includes anesthesia devices and ventilators, thermoregulation equipment, hospitable consumables and accessories, supply units, lights, gas management systems, patient monitoring, software applications, system products, and other services. The company's product portfolio also comprises stationary and mobile gas detection systems, personal protective equipment, and alcohol and drug testing devices. In addition, it offers various training and services, as well as fire training facilities for firefighters. The company was founded in 1889 and is headquartered in Lübeck, Germany. Drägerwerk AG & Co. KGaA operates as a subsidiary of Stefan DrÄGer Gmbh. Read Less
Drägerwerk AG & Co. KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency medicine, perioperative care, intensive care, and perinatal medicine....Read More
Frequently Asked Questions About Drägerwerk AG & Co. KGaA (DGWPF) Stock
Stock Target Advisor's fundamental analysis for Drägerwerk AG & Co. KGaA's stock is Slightly Bullish .
DGWPF stock's dividend yield is 0.28%.
Our analysis grades DGWPF stock's dividend yield at F. This means that DGWPF stock's dividend yield is above 7% of the stocks in the Medical Devices sector in the OTC exchange.
Based on this DGWPF may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on DGWPF's stock to indicate what its average analyst target is.
DGWPF stock's Price/Earning ratio is 9.57.
Our analysis grades DGWPF stock's Price / Earning ratio at D+. This means that DGWPF stock's Price/Earning ratio is above 32.99999999999999% of the stocks in the Medical Devices sector in the OTC exchange.
Based on this DGWPF may be fairly valued for its sector
The last closing price of DGWPF's stock was USD 51.00.
The most recent market capitalization for DGWPF is USD 0.89B.
Unfortunately we do not have enough analyst data on DGWPF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Drägerwerk AG & Co. KGaA's stock.
As per our most recent records Drägerwerk AG & Co. KGaA has 15,171 Employees.
Drägerwerk AG & Co. KGaA's registered address is Moislinger Allee 53-55, Lübeck, Germany, 23558.
You can get more information about it from Drägerwerk AG & Co. KGaA's website at https://www.draeger.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for DGWPF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
